Published In
European Journal of Rheumatology
Volume 9 · Issue 2
Pages: 108-110
History
Published Online: April 26, 2022
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © 2022 European Journal of Rheumatology
Brigitte Kazzi
Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Brent Gudenkauf
Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Derek Fine
Division of Nephrology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Jose Manuel Monroy-Trujillo
Division of Nephrology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Antoine Azar
Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Gabriel Giannini
Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
Homa Timlin
Division of Rheumatology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Kazzi, B., Gudenkauf, B., Fine, D., Monroy-Trujillo, J. M., Azar, A., Giannini, G., & Timlin, H. (2022). Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature. European Journal of Rheumatology, 9(2), 108–110. https://doi.org/10.5152/eurjrheum.2022.21059
Full Text
Full Text PDF
Full Text PDF
Abstract
Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn’s disease on long-term adalimumab treatment presented with new-onset Raynaud’s phenomenon and was found to have hematuria and proteinuria. Elevated antinuclear, anti-dsDNA, and MPO antibodies were found. A renal biopsy confirmed the diagnosis of lupus nephritis. Adalimumab was discontinued ensuing improvement in urine studies and resolution of dsDNA and MPO antibodies. Adalimumab can induce systemic lupus erythematosus and lupus nephritis.
Cite this article as: Kazzi B, Gudenkauf B, Fine D, et al. Adalimumab-induced lupus nephritis: Case report and review of the literature. Eur J Rheumatol. 2022;9(2): 108-110.
Article Info
Published In
Journal
European Journal of Rheumatology
Volume / Issue
Volume 9 · Issue 2
Pages
108-110
History
Published Online
April 26, 2022
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
Copyright (c) 2022 European Journal of Rheumatology
Affiliations
Brigitte Kazzi
Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Brent Gudenkauf
Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Derek Fine
Division of Nephrology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Jose Manuel Monroy-Trujillo
Division of Nephrology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Antoine Azar
Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Gabriel Giannini
Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
Homa Timlin
Division of Rheumatology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA
Cite this Article
Kazzi, B., Gudenkauf, B., Fine, D., Monroy-Trujillo, J. M., Azar, A., Giannini, G., & Timlin, H. (2022). Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature. European Journal of Rheumatology, 9(2), 108–110. https://doi.org/10.5152/eurjrheum.2022.21059
Outlines